Stifel lowered the firm’s price target on Inventiva (IVA) to $15 from $17 and keeps a Buy rating on the shares. The firm notes the company is in final stretches of its pivotal NATiV3 of lanifibranor/Lani in MASH, which reads out in Q4 2026. Expectations for this trial success are high given the strong powering, longer duration trial, and the well-screened population, Stifel adds. In parallel, Inventiva is establishing the Lani profile for its ability to address the underlying metabolic dysfunction related to liver disease – making it ideally suited for the T2D MASH population. Though the market is served by Rezdiffra and Wegovy, Stifel believes Lani can find clear positioning within this commercial offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- Inventiva Posts Deeper 2025 Loss but Extends Cash Runway Ahead of Key MASH Phase 3 Readout
- Inventiva management to meet with Piper Sandler
- Lanifibranor’s Emerging Role in the MASH Market: Physician Sentiment and Uptake Potential Support a Buy Rating Despite Cash Constraints
- Inventiva initiated with a Buy at Truist
- Inventiva: Strong Balance Sheet and Late-Stage MASH Candidate Lanifibranor Drive Compelling Buy Rating